In an interview with Pharmacy Times, Biykem Bozkurt, MD, PhD, professor of medicine and senior dean at Baylor College of Medicine and principal investigator of the SYNCHRONIZE-CVOT trial, discussed how pharmacists should approach gastrointestinal (GI) adverse effects and titration with survodutide. The discussion centered around new data from SYNCHRONIZE-CVOT (NCT06077864), the phase 3 cardiovascular outcomes trial of survodutide presented at the American Heart Association Scientific Sessions 2026.
Key Takeaways
- Bozkurt said rigid dose escalation contributed to GI adverse effects and that titration should reflect individual tolerability and adherence
- Clinicians should know whether patients are taking over-the-counter or compounded products, Bozkurt said, and pharmacists are well positioned to identify them.
- Bozkurt encouraged pharmacists to educate patients on multidomain cardiometabolic risk reduction, including lipids, hemoglobin A1C, waist circumference, and blood pressure, rather than the amount of weight lost.
Bozkurt said the initial protocol across the SYNCHRONIZE program mandated rigid dose escalation during the first 24 weeks, and GI adverse effects were higher than with placebo, as is common with other incretin-based therapies. She argued that titration should be individualized to each patient's tolerability and ability to adhere to a dose and said flexibility in SYNCHRONIZE-CVOT allowed participants to remain on the drug. In a while-on-treatment analysis, point estimates for the combined cardiovascular end points trended in a more favorable direction among participants who stayed on therapy, although she emphasized that the noninferiority trial was not powered to assess superiority.
Bozkurt described pharmacists as critical to identifying individual needs, tolerability, and adverse effect profiles. She also noted drop-in use of other marketed products in the placebo group and said clinicians should know what patients may be taking over the counter or as compounded products. Beyond tolerability, Bozkurt urged pharmacists to educate patients about cardiovascular and cardiometabolic benefits rather than the magnitude of weight loss alone.
She said individuals living with obesity should be screened for diabetes, metabolic dysfunction-associated steatotic liver disease and steatohepatitis, chronic kidney disease, dyslipidemia, hypertension, and cardiovascular disease. She also referenced a separate AHA abstract showing that survodutide helped participants reach treatment targets for lipids, hemoglobin A1C, waist circumference, and blood pressure earlier and more comprehensively than placebo.